Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ( FY 2021 ), and an outlook statement. UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the £4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ( Excalibur ). · Cash and cash equivalents were £23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: £31.7 million au
Sensyne Health signs second US research agreement
All data supplied to Sensyne for research will be anonymised by CCPM and will remain in the US. The provision of the data will operate under an agreed set of data processing procedures
Sensyne Health PLC (LON:SENS) has signed a strategic research agreement with the Colorado Center for Personalized Medicine (CCPM).
It is the second strategic research agreement in the US signed by Sensyne, which uses artificial intelligence (AI) technology to ethically use mass patient data to support medical research; the company announced a similar agreement last Friday with St Luke s University Health Network in Pennsylvania.
New agreement covering 2.5 million patients brings Sensyne's combined total of anonymized and de-identified patient data for medical research to 10.9 million patients First agreement by clinical
Kingfisher still taking bashing from Thursday s statement
A look at Friday s major share movers on the London Stock Exchange
Kingfisher PLC (LON:KGF) lost 5% to 356.8p as it was still taking a bashing from Thursday s first-quarter trading statement that was not quite strong enough to keep the share price momentum going.
Like-for-like (LFL) sales in the three months ended April 30 were up 64.2% year-on-year, with a strong performance in the UK and France, despite COVID-related restrictions affecting its French outlets through most of the quarter.
The company raised the LFL sales outlook for the first half of the current fiscal year, with the company now expecting the growth rate to be in the mid-to-high teens, up from previous expectations of a low double-digit percentage increase. Guidance for the second half of the financial year has been left unchanged.
Sensyne Health Signs First US Strategic Research Agreement with St Luke s University Health Network streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.